Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

CEO resigns as Eli Lilly (LLY) dominates the weight loss drug market and compounders threaten the company's financial outlook ...

Novo Nordisk (NVO) stock falls as the company CEO Lars Fruergaard Jørgensen steps down after 8 years of leadership marked by ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S (NYSE:NVO ...

The CEO of Danish pharmaceutical giant Novo Nordisk, known for its blockbuster weight-loss drug Ozempic, will step down, the ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Novo Nordisk CEO Lars Fruergaard Jorgensen will step down as the company faces challenges in the obesity drug market, which ...

Novo Nordisk announced the resignation of CEO Lars Fruergaard Jorgensen amidst recent market challenges and fluctuating share prices. The company will conduct a search for a successor as Jorgensen ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—heads for the exit. | Under a mutual agreement with ...